BACKGROUND: Bamlanivimab and casirivimab-imdevimab are authorized for treatment of mild to moderate coronavirus disease 2019 (COVID-19) in high-risk patients. We compared the outcomes of patients who received these therapies to identify factors associated with hospitalization and other clinical outcomes. METHODS: Adult patients who received monoclonal antibody from 19 November 2020 to 11 February 2021 were selected and divided into those who received bamlanivimab (n = 2747) and casirivimab-imdevimab (n = 849). The 28-day all-cause and COVID-19-related hospitalizations were compared between the groups. RESULTS: The population included 3596 patients; the median age was 62 years, and 50% were female. All had ≥1 medical comorbidity; 55% had multiple comorbidities. All-cause and COVID-19-related hospitalization rates at 28 days were 3.98% and 2.56%, respectively. After adjusting for medical comorbidities, there was no significant difference in all-cause and COVID-19-related hospitalization rates between bamlanivimab and casirivimab-imdevimab (adjusted hazard ratios [95% confidence interval], 1.4 [.9-2.2] and 1.6 [.8-2.7], respectively). Chronic kidney, respiratory and cardiovascular diseases, and immunocompromised status were associated with higher likelihood of hospitalization. CONCLUSIONS: This observational study on the use of bamlanivimab and casirivimab-imdevimab in high-risk patients showed similarly low rates of hospitalization. The number and type of medical comorbidities are associated with hospitalizations after monoclonal antibody treatment.
BACKGROUND: Bamlanivimab and casirivimab-imdevimab are authorized for treatment of mild to moderate coronavirus disease 2019 (COVID-19) in high-risk patients. We compared the outcomes of patients who received these therapies to identify factors associated with hospitalization and other clinical outcomes. METHODS: Adult patients who received monoclonal antibody from 19 November 2020 to 11 February 2021 were selected and divided into those who received bamlanivimab (n = 2747) and casirivimab-imdevimab (n = 849). The 28-day all-cause and COVID-19-related hospitalizations were compared between the groups. RESULTS: The population included 3596 patients; the median age was 62 years, and 50% were female. All had ≥1 medical comorbidity; 55% had multiple comorbidities. All-cause and COVID-19-related hospitalization rates at 28 days were 3.98% and 2.56%, respectively. After adjusting for medical comorbidities, there was no significant difference in all-cause and COVID-19-related hospitalization rates between bamlanivimab and casirivimab-imdevimab (adjusted hazard ratios [95% confidence interval], 1.4 [.9-2.2] and 1.6 [.8-2.7], respectively). Chronic kidney, respiratory and cardiovascular diseases, and immunocompromised status were associated with higher likelihood of hospitalization. CONCLUSIONS: This observational study on the use of bamlanivimab and casirivimab-imdevimab in high-risk patients showed similarly low rates of hospitalization. The number and type of medical comorbidities are associated with hospitalizations after monoclonal antibody treatment.
Authors: Raymund R Razonable; Ravindra Ganesh; Rachel K Bishop; Tracy L Culbertson; Molly Destro Borgen; Michelle C Hedin; Laura H Hopkins; Tammy A Jackson; Jennifer J Larsen; Jennifer A Matoush; Darcie E Moehnke; Shelly M Olson; Kellie M Peterson; Jordan Rosedahl; Lindsey M Philpot Journal: J Patient Exp Date: 2022-06-23
Authors: Raymund R Razonable; John C O'Horo; Douglas W Challener; Lori Arndt; Richard F Arndt; Caroline G Clune; Tracy L Culbertson; Scott T Hall; Alexander Heyliger; Tammy A Jackson; Brian D Kennedy; Jennifer Larsen; Sara N Hanson; Perry W Sweeten; Sidna M Tulledge-Scheitel; Ravindra Ganesh Journal: Mayo Clin Proc Date: 2022-06-23 Impact factor: 11.104
Authors: Aneesh Puthiyedath Joy; Anitha Theresa Augustine; Mohammed Salim Karattuthodi; Jaffer Chalil Parambil; Dilip Chandrasekher; P Danisha; Linu Mohan Panakkal; Madhav A Joshi; K T Azharul Haque; Irshad K Mohammed Izudheen; Shadia Badaruddeen; Riya Sara John; Sarath Murali; Ardhra Rose Thomas; Fathimath Sahla; Shahir Ahmed Kv Ahmed Unni; Raseel Omar Ahmed; Shinu Cholamugath Journal: Clin Epidemiol Glob Health Date: 2022-01-19
Authors: Emily B Rubin; Jonathan A Boiarsky; Lauren A Canha; Anita Giobbie-Hurder; Mofei Liu; Matthew J Townsend; Michael Dougan Journal: Open Forum Infect Dis Date: 2021-11-03 Impact factor: 3.835
Authors: John C O'Horo; Douglas W Challener; Leigh Speicher; Wendelyn Bosch; Maria Teresa Seville; Dennis M Bierle; Ravindra Ganesh; Caroline G Wilker; Richard F Arndt; Lori L Arndt; Sidna M Tulledge-Scheitel; Sara N Hanson; Raymund R Razonable Journal: Mayo Clin Proc Date: 2021-12-16 Impact factor: 7.616